About Outlook Therapeutics, Inc.

Website
Website
Employees
Employees
11-50 employees View all
Industry
Industry
Biotechnology
Location
Location
7 Clarke Dr, Cranbury, New Jersey 08512, US
Description
Information
Outlook Therapeutics, Inc. | 6,953 followers on LinkedIn. ONS-5010: A uniquely positioned anti-VEGF therapy for wet AMD, DME and BRVO | Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S.

Outlook Therapeutics, Inc. Alternatives

Frequently Asked Questions about Outlook Therapeutics, Inc.

What is Outlook Therapeutics, Inc. email format?

The widely used Outlook Therapeutics, Inc. email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.


What is Outlook Therapeutics, Inc. customer service number?

To contact Outlook Therapeutics, Inc. customer service number in your country click here to find.


Who is the CEO of Outlook Therapeutics, Inc.?

Russ Trenary is the CEO of Outlook Therapeutics, Inc.. To contact Russ Trenary email at [email protected] or [email protected].


Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut

Search Portal

Find countless prospects outside of LinkedIn fast

Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.

Discover the source of our data

Learn more